Share Price and Basic Stock Data
Last Updated: January 22, 2026, 9:32 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesis IBRC India Ltd operates in the seeds, tissue culture, and biotechnology industry, with its stock currently priced at ₹81.7 and a market capitalization of ₹106 Cr. The company has faced significant challenges, as evidenced by its sales figures, which have consistently stood at ₹0.00 from Mar 2023 through Mar 2025, with only a marginal revenue of ₹3.67 Cr reported in September 2024. This stark absence of revenue highlights operational inefficiencies and raises concerns about the company’s ability to generate income despite its presence in a growing sector. The trend of zero sales over multiple quarters indicates potential issues in product development or market penetration, which is critical in a highly competitive industry. Furthermore, the absence of foreign institutional and domestic institutional investors suggests a lack of confidence in the company’s growth trajectory. Overall, the revenue trends reflect a troubling stagnation that warrants close scrutiny from existing and potential investors.
Profitability and Efficiency Metrics
Genesis IBRC India Ltd has exhibited poor profitability metrics, with a net profit of -₹0.23 Cr as of the latest reporting period. The company recorded operating profits of -₹3.69 Cr for Mar 2024 and -₹0.17 Cr for Mar 2025, indicating a persistent struggle to control operational expenses, which amounted to ₹3.80 Cr for Mar 2024. The operating profit margin (OPM) for the same period was reported at a staggering 95.37%, primarily due to an anomaly in the revenue recognition process in September 2024, where a significant operating profit of ₹3.65 Cr was recorded. This raises questions about the sustainability of such margins. Moreover, with a return on equity (ROE) and return on capital employed (ROCE) both standing at 51.6%, the company has demonstrated high efficiency in utilizing its equity and capital despite the lack of revenue generation. However, the negative net profit and high expenses indicate that the company must address its operational challenges to leverage these efficiency metrics effectively.
Balance Sheet Strength and Financial Ratios
The balance sheet of Genesis IBRC India Ltd presents a mixed picture. Total assets stood at ₹8.51 Cr as of September 2025, while total liabilities were reported at ₹8.83 Cr, indicating a negative net worth situation. Reserves have steadily declined, reaching -₹4.65 Cr, reflecting ongoing financial distress. The company’s borrowings are notably absent at ₹0.00 Cr, which could be interpreted as a cautious approach to debt management. Nevertheless, the interest coverage ratio (ICR) of 6.83x suggests that the company can comfortably meet any interest obligations, should they arise. The price-to-book value ratio stands at 0.71x, indicating that the stock is undervalued relative to its book value. However, the overall financial ratios signal a need for significant improvements in profitability and asset management to strengthen the company’s financial position. The absence of substantial reserves raises concerns about the company’s ability to weather financial downturns.
Shareholding Pattern and Investor Confidence
Genesis IBRC India Ltd has a stable shareholding pattern, with promoters holding 11.33% and the public holding a substantial 88.68% of the company’s shares. The total number of shareholders as of September 2025 is recorded at 1,736, indicating a broad base of public participation. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could reflect a lack of confidence in the company’s future prospects. The consistent promoter shareholding percentage suggests a commitment to the company’s long-term strategy. Nonetheless, the high public stake combined with low institutional interest may lead to volatility in stock performance, especially in light of the company’s financial struggles and stagnant revenue. This pattern indicates that while there is a level of retail investor confidence, institutional investors are likely waiting for clearer signs of recovery and growth before committing capital.
Outlook, Risks, and Final Insight
Looking ahead, Genesis IBRC India Ltd faces significant risks, primarily stemming from its inability to generate consistent revenue and its declining reserves. The company must focus on operational efficiencies and product development to turn around its financial performance. Additionally, the absence of institutional investors could hinder its ability to raise capital for future growth. However, the high ROE and ROCE metrics suggest that if revenue generation can be re-established, the company has the potential to deliver substantial returns. The unique position within the biotechnology sector, coupled with a commitment from promoters, may provide a foundation for future recovery. In scenarios where the company successfully pivots to profitable operations, it could attract institutional interest and regain investor confidence. Conversely, failure to address operational inefficiencies could lead to further financial deterioration, impacting its viability in the competitive biotechnology landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 6.99 Cr. | 22.9 | 70.9/21.0 | 12.8 | 0.00 % | 11.8 % | 9.69 % | 10.0 | |
| Genesis IBRC India Ltd | 94.9 Cr. | 73.0 | 185/18.3 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 125 Cr. | 13.7 | 20.3/10.7 | 12.5 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 267 Cr. | 141 | 239/136 | 5.67 | 362 | 1.42 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 28.8 Cr. | 21.0 | 34.8/19.3 | 37.4 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 196.00 Cr | 54.32 | 18.52 | 81.79 | 0.28% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.01 | 0.02 | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.10 | 0.02 | 0.03 | 0.02 | 0.12 | 0.06 |
| Operating Profit | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 |
| OPM % | 99.46% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 | -0.06 |
| EPS in Rs | -0.01 | -0.02 | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 | -0.05 |
Last Updated: December 26, 2025, 7:46 pm
Below is a detailed analysis of the quarterly data for Genesis IBRC India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.12 Cr. (Jun 2025) to 0.06 Cr., marking a decrease of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.06 Cr.. The value appears strong and on an upward trend. It has increased from -0.12 Cr. (Jun 2025) to -0.06 Cr., marking an increase of 0.06 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.06 Cr.. The value appears strong and on an upward trend. It has increased from -0.12 Cr. (Jun 2025) to -0.06 Cr., marking an increase of 0.06 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.06 Cr.. The value appears strong and on an upward trend. It has increased from -0.12 Cr. (Jun 2025) to -0.06 Cr., marking an increase of 0.06 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.05. The value appears strong and on an upward trend. It has increased from -0.09 (Jun 2025) to -0.05, marking an increase of 0.04.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.23 |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | -0.23 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | ||||||||
| Other Income | 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | -0.23 |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.33% | 179.55% | -100.00% | 75.00% | -100.00% | -20.00% | 0.00% | -16.67% | -2614.29% | 192.11% |
| Change in YoY Net Profit Growth (%) | 0.00% | 212.88% | -279.55% | 175.00% | -175.00% | 80.00% | 20.00% | -16.67% | -2597.62% | 2806.39% |
Genesis IBRC India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 106% |
| 3 Years: | 215% |
| TTM: | 191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 40% |
| 3 Years: | 54% |
| 1 Year: | 152% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | 52% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 10, 2025, 4:22 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | -3.25 | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -4.65 |
| Borrowings | 0.61 | 0.17 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.90 | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 0.16 |
| Total Liabilities | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Fixed Assets | 1.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.18 | 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Total Assets | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
Below is a detailed analysis of the balance sheet data for Genesis IBRC India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is -4.65 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -4.47 Cr. (Mar 2025) to -4.65 Cr., marking a decline of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing). It has decreased from 0.30 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.14 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.51 Cr.. The value appears to be improving (decreasing). It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Total Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.65 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.77 | -0.32 | -0.27 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -0.03 |
| Diluted EPS (Rs.) | -0.03 |
| Cash EPS (Rs.) | 0.04 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.39 |
| Revenue From Operations / Share (Rs.) | 3.33 |
| PBDIT / Share (Rs.) | 0.14 |
| PBIT / Share (Rs.) | 0.06 |
| PBT / Share (Rs.) | 0.04 |
| Net Profit / Share (Rs.) | -0.02 |
| NP After MI And SOA / Share (Rs.) | -0.02 |
| PBDIT Margin (%) | 4.20 |
| PBIT Margin (%) | 2.02 |
| PBT Margin (%) | 1.41 |
| Net Profit Margin (%) | -0.78 |
| NP After MI And SOA Margin (%) | -0.78 |
| Return on Networth / Equity (%) | -0.35 |
| Return on Capital Employeed (%) | 0.87 |
| Return On Assets (%) | -0.27 |
| Current Ratio (X) | 3.24 |
| Quick Ratio (X) | 3.00 |
| Interest Coverage Ratio (X) | 6.83 |
| Interest Coverage Ratio (Post Tax) (X) | -0.27 |
| Enterprise Value (Cr.) | 6.58 |
| EV / Net Operating Revenue (X) | 1.52 |
| EV / EBITDA (X) | 36.12 |
| MarketCap / Net Operating Revenue (X) | 1.59 |
| Price / BV (X) | 0.71 |
| Price / Net Operating Revenue (X) | 1.59 |
After reviewing the key financial ratios for Genesis IBRC India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 18, the value is 0.04. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 18, the value is 3.33. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 18, the value is 0.14. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 18, the value is 0.06. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 18, the value is 0.04. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 18, the value is 4.20. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 18, the value is 2.02. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 18, the value is 1.41. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 18, the value is -0.35. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 18, the value is 0.87. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 18, the value is 3.24. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 18, the value is 3.00. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 6.83. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 18, the value is 6.58. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 18, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 18, the value is 36.12. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 18, the value is 0.71. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesis IBRC India Ltd:
- Net Profit Margin: -0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.87% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.35% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 18.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Flat No.401, VVN Residency, 40-A, Ashok Nagar, Eluru Andhra Pradesh 534002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Balakrishna Koppula | Whole Time Director |
| Mrs. Vanitha Nagulavari | Non Executive Director |
| Mr. Prasada Rao Kalluri | Independent Director |
| Mr. Mohammed Baba | Independent Director |
FAQ
What is the intrinsic value of Genesis IBRC India Ltd?
Genesis IBRC India Ltd's intrinsic value (as of 22 January 2026) is ₹39.86 which is 45.40% lower the current market price of ₹73.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹94.9 Cr. market cap, FY2025-2026 high/low of ₹185/18.3, reserves of ₹-4.65 Cr, and liabilities of ₹8.51 Cr.
What is the Market Cap of Genesis IBRC India Ltd?
The Market Cap of Genesis IBRC India Ltd is 94.9 Cr..
What is the current Stock Price of Genesis IBRC India Ltd as on 22 January 2026?
The current stock price of Genesis IBRC India Ltd as on 22 January 2026 is ₹73.0.
What is the High / Low of Genesis IBRC India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesis IBRC India Ltd stocks is ₹185/18.3.
What is the Stock P/E of Genesis IBRC India Ltd?
The Stock P/E of Genesis IBRC India Ltd is .
What is the Book Value of Genesis IBRC India Ltd?
The Book Value of Genesis IBRC India Ltd is 6.42.
What is the Dividend Yield of Genesis IBRC India Ltd?
The Dividend Yield of Genesis IBRC India Ltd is 0.00 %.
What is the ROCE of Genesis IBRC India Ltd?
The ROCE of Genesis IBRC India Ltd is 51.6 %.
What is the ROE of Genesis IBRC India Ltd?
The ROE of Genesis IBRC India Ltd is 51.6 %.
What is the Face Value of Genesis IBRC India Ltd?
The Face Value of Genesis IBRC India Ltd is 10.0.